<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098977</url>
  </required_header>
  <id_info>
    <org_study_id>HeaRt-V-AMI</org_study_id>
    <nct_id>NCT05098977</nct_id>
  </id_info>
  <brief_title>The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>HeaRt-V-AMI</acronym>
  <official_title>The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction: From Primary Angioplasty to Secondary Long-term Prevention - a Single Centre, Prospective, Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grigore T. Popa University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grigore T. Popa University of Medicine and Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aims&#xD;
&#xD;
        -  heart rate variability (HRV) assessment in patients with acute myocardial infarction who&#xD;
           undergo primary percutaneous coronary intervention (PCI);&#xD;
&#xD;
        -  measurement of HRV using a device approved for medical use in Europe;&#xD;
&#xD;
        -  assessment of the correlation between HRV and short- and long-term adverse&#xD;
           cardiovascular events (composite of all-cause mortality and major adverse cardiovascular&#xD;
           events - MACE; ventricular arrhythmias; hospital admissions for heart failure; left&#xD;
           ventricular systolic and diastolic disfunction; MACE in special subgroups of patients -&#xD;
           elderly, diabetes mellitus, chronic kidney disease) in patients treated by primary PCI&#xD;
           for acute myocardial infarction;&#xD;
&#xD;
        -  creating a registry of HRV parameters measured in a contemporary cohort of patients with&#xD;
           acute myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following data will be collected:&#xD;
&#xD;
        -  general demographic data;&#xD;
&#xD;
        -  time from chest pain onset to primary PCI;&#xD;
&#xD;
        -  comorbidities (ischemic heart disease, arterial hypertension, previous PCI or coronary&#xD;
           artery bypass surgery - CABG, heart failure, peripheral artery disease, atrial&#xD;
           fibrillation, stroke, diabetes mellitus, kidney disease);&#xD;
&#xD;
        -  cardiovascular risk factors (age, body mass index, smoking, abdominal perimeter,&#xD;
           sedentarism, gender, inflammation);&#xD;
&#xD;
        -  cardiac rhythm derived from electrocardiographic data;&#xD;
&#xD;
        -  HRV time- and frequency domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF,&#xD;
           LF/HF ratio);&#xD;
&#xD;
        -  routine biological data and biomarkers, including creatine kinase-MB (CK-MB), aspartate&#xD;
           transaminase (AST), lactate dehydrogenase (LDH) and cardiac-specific troponin;&#xD;
&#xD;
        -  left ventricular ejection fraction at admission, at discharge and at follow-up (1 month,&#xD;
           6 months and 1 year);&#xD;
&#xD;
        -  initial and final thrombolysis in myocardial infarction (TIMI) flow;&#xD;
&#xD;
        -  type of stent used for coronary angioplasty;&#xD;
&#xD;
        -  Global Registry of Acute Coronary Events (GRACE) score;&#xD;
&#xD;
        -  SYNTAX score II in case of three-vessel coronary disease or involving left main stem;&#xD;
&#xD;
        -  in-hospital, one month and long-term clinical outcomes (composite of all-cause mortality&#xD;
           and major adverse cardiovascular events - MACE; ventricular arrhythmias; hospital&#xD;
           admissions for heart failure; left ventricular systolic and diastolic disfunction; MACE&#xD;
           in special subgroups of patients - elderly, diabetes mellitus, chronic kidney disease).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality and major adverse cardiovascular events (MACE)</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>MACE will be defined as cardiac mortality, fatal and non-fatal myocardial infarction, unplanned target vessel revascularization and stroke)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as total number of deaths from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as number of deaths due to cardiac causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal and non-fatal myocardial infarction</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as a new myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as unplanned PCI or coronary artery bypass graft surgery for a stenosis in another part of the vessel treated at the index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as repeat PCI or coronary artery bypass graft surgery of the target lesion treated at the index PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as ischemic or hemorrhagic stroke</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital admissions for heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as any subsequent admission for a primary diagnosis of heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular arrhythmias</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Defined as electrocardiographic documentation of ventricular fibrillation or sustained ventricular tachycardia</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Appraised using two-dimensional transthoracic echocardiography - Simpsons method</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular diastolic dysfunction</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>Appraised using two-dimensional transthoracic echocardiography - E/A and E/e prime ratios</description>
  </other_outcome>
  <other_outcome>
    <measure>Composite of all-cause mortality and major adverse cardiovascular events in special subgroup of patients</measure>
    <time_frame>in-hospital, 1 month and 1 year</time_frame>
    <description>elderly, diabetes mellitus, chronic kidney disease</description>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Autonomic Dysfunction</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heart rate variability measurement</intervention_name>
    <description>HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.</description>
    <other_name>PCI</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CK-MB, AST, LDH, cardiac-specific troponin, glycemia, glycosylated hemoglobin, lipid profile,&#xD;
      complete blood count, hemoglobin, hematocrit, serum urea and creatinine (estimated glomerular&#xD;
      filtration rate using CKD-EPI equation), serum potassium and sodium, sideremia, plasma&#xD;
      ferritin, thyroid-stimulating hormone, serum thyroxine, C-reactive protein, N-terminal pro&#xD;
      b-type natriuretic peptide.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with STEMI referred to catheterization laboratory from Institute of Cardiovascular&#xD;
        Diseases &quot;Prof. George IM Georgescu&quot;, Iasi, within 12 hours from symptoms onset.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with ST-Elevation Myocardial Infarction (STEMI) treated with primary PCI&#xD;
             within 12 hours from symptoms onset;&#xD;
&#xD;
          -  patients in sinus rhythm;&#xD;
&#xD;
          -  patients who have read and signed the standard informed consent regarding enrolment in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unconscious or intubated patients who are unable to sign the standard informed&#xD;
             consent;&#xD;
&#xD;
          -  patients with atrial fibrillation;&#xD;
&#xD;
          -  patients with sinus node dysfunction or atrioventricular block of any degree;&#xD;
&#xD;
          -  frequent premature supraventricular or ventricular contractions;&#xD;
&#xD;
          -  paced ventricular rhythm;&#xD;
&#xD;
          -  patients treated with positive inotropic and chronotropic drugs;&#xD;
&#xD;
          -  history of myocardial infarction or myocardial revascularization (PCI or CABG);&#xD;
&#xD;
          -  patients refusal.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Covic, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Gr T Popa University of Medicine and Pharmacy Iasi ROMANIA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandru Burlacu, MD, PhD</last_name>
    <phone>+40744488580</phone>
    <email>alexandru.burlacu@umfiasi.ro</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Crischentian Brinza, MD</last_name>
    <phone>+40758431764</phone>
    <email>crischentian.brinza@d.umfiasi.ro</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Interventional Cardiology, Institute of Cardiovascular Diseases &quot;Prof. George IM Georgescu&quot; Iasi</name>
      <address>
        <city>Iaşi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
    <contact>
      <last_name>Crischentian Brinza, MD</last_name>
      <phone>+40758431764</phone>
      <email>crischentian.brinza@d.umfiasi.ro</email>
    </contact>
    <investigator>
      <last_name>Adrian Covic, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandru Burlacu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariana Floria, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grigore T. Popa University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Professor Adrian Covic</investigator_full_name>
    <investigator_title>Professor coordinator</investigator_title>
  </responsible_party>
  <keyword>Heart rate variability</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Drug-eluting stents</keyword>
  <keyword>Risk assessment</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Major adverse cardiovascular events</keyword>
  <keyword>Left ventricular ejection fraction</keyword>
  <keyword>Secondary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

